Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

BACKGROUND: Due to limited therapeutic options, the spread of extended-spectrum beta-lactamases (ESBLs) have become a major public health concern. We conducted a prospective, randomized, open-label comparison of the therapeutic efficacy of piperacillin-tazobactam (PTZ), cefepime, and ertapenem in fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Yu Bin, Lee, Jacob, Kim, Young Keun, Lee, Seung Soon, Lee, Jeong-a, Kim, Hyo Youl, Uh, Young, Kim, Han-Sung, Song, Wonkeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463388/
https://www.ncbi.nlm.nih.gov/pubmed/28592240
http://dx.doi.org/10.1186/s12879-017-2502-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463388/
https://www.ncbi.nlm.nih.gov/pubmed/28592240
http://dx.doi.org/10.1186/s12879-017-2502-x

Ejemplares similares